Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system-Reference-Cited by-同舟云学术

Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system

Published:2017-11-06 Issue:1 Volume:27 Page:30-37
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Gagne Joshua J.¹^ORCID,Houstoun Monika²,Reichman Marsha E.²^ORCID,Hampp Christian²,Marshall James H.³,Toh Sengwee³^ORCID

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine; Brigham and Women's Hospital and Harvard Medical School; Boston MA USA

2. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research; Food and Drug Administration; Silver Spring MD USA

3. Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Health Care Institute; Boston MA USA

Funder

U.S. Food and Drug Administration

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference25 articles.

1. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy;Boden;New Eng J Med,2011

2. Niaspan (niacin extended-release) prescribing information AbbVie, Inc http://www.rxabbvie.com/pdf/niaspan.pdf

3. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia;Maccubbin;Int J Clin Pract,2008

4. CHMP assessment report for Tredaptive European Medicines Agency 2008 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000889/WC500042219.pdf

5. Effects of extended-release niacin with laropiprant in high-risk patients;Landray;New Eng J Med,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease;Reviews in the Neurosciences;2023-04-10

2. Distributed research networks and applications to pragmatic randomized trials;Pragmatic Randomized Clinical Trials;2021

3. Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence;Pharmacoepidemiology and Drug Safety;2020-08-28

4. Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models;Pharmacoepidemiology;2019-10-18

5. Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making;Clinical Pharmacology & Therapeutics;2019-02-25